DPP4 and type 2 diabetes mellitus: In the clinical trial setting, trelagliptin showed sustained inhibition of DPP-4 activity until 7 days after dosing in the phase 2 dose-ranging study in patients with type 2 diabetes mellitus (T2DM) [2].